Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

ClinicalTrials.gov ID: NCT00135876

Public ClinicalTrials.gov record NCT00135876. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:10 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

In patients with malignant glioma, to determine the efficacy of prophylaxis with LMWH (dalteparin) compared to placebo, both commenced beyond the immediate postoperative period, for the prevention of VTE.

Study identification

NCT ID: NCT00135876
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Ontario Clinical Oncology Group (OCOG); Other
Enrollment: 512 participants

Conditions and interventions

Conditions

Interventions

dalteparin Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2002 (Type not available)
Primary completion: Not listed
Completion: Nov 2006 (Actual)
Last update posted: Apr 27, 2007

2002 – 2006

United States locations

U.S. sites: 3
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Kellogg Cancer Center - Evanston Northwestern Healthcare	Evanston	Illinois	60201	—
Henry Ford Hospital	Detroit	Michigan	48202	—
Huntsman Cancer Institute	Salt Lake City	Utah	84112-5550	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00135876, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 27, 2007 · Synced Nov 3, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00135876 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →